Project Grant R01AI192636
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$721K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This Project Grant award of $536,871 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify pan-arenavirus sites of vulnerability through machine learning and artificial neural network molecular screening of small molecules against arenavirus glycoprotein complexes (GPC) and RNA polymerases (RNAP). The proposed research seeks to define molecular specificities and commonalities across...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop new malaria vaccine candidates based on the Pf Glutamic Acid Rich Protein (PFGARP) antigen. The $412,500 award will be used by the University of South Florida to evaluate immunodominant fragments of PFGARP for potential inclusion in a malaria vaccine, with a focus on improving efficacy against the deadly Plasmodium...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) will support research to define the immune response to Plasmodium vaccination and test an adjuvant to boost immunity against malaria. The $205,125 award to the Hennepin Healthcare Research Institute will utilize an improved small animal model to compare vaccine responses in specific pathogen-free (SPF) mice versus...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $247,236 to the Regents of the University of Minnesota to investigate the expansion and function of long-lived effector CD8 T cells in the mature memory compartment. The research aims to determine the proinflammatory cytokines that support the formation and persistence of this T cell population, as well as how...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding the development of a novel T cell-based vaccine to prevent dengue and Zika virus infections. The $781,718 award to Loyola University of Chicago will support the design and evaluation of a vaccine candidate that targets the Zika and dengue virus non-structural protein 3 (NS3) with the goal of inducing cytotoxic T lymphocyte responses without...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $790,000.00 in funding to the Regents of the University of Minnesota to conduct research on the immune response to West Nile virus (WNV) and the factors that influence the development of neuroinvasive disease. The goal is to gain a molecular understanding of WNV neuroinvasion, central nervous system immunity, and the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,248,576 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The grant, awarded on July 25, 2025, will fund research to understand the cross-protective efficacy of the recently FDA-approved IXCHIQ live attenuated chikungunya virus vaccine against other alphavirus species, assess the vaccine's infectivity and transmissibility in mosquitoes, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $437,250 to the Regents of the University of Minnesota to conduct research on using extracellular vesicle-associated adeno-associated virus (EV-AAV) vectors for gene therapy targeting the airway epithelium in non-human primates. The goal is to achieve efficient and widespread transgene expression, particularly in the airway basal stem cells, to...